Klaria is a leading brand in the development of new pharmaceuticals with a focus on their Alginatfilm technology. Their breakthrough technology allows for the delivery of drugs through the buccal mucosa, making it possible to administer medications that are not orally available and currently need to be given as injections. Their strategy centers on addressing significant medical needs by replacing existing treatments that are available only through injections or nasal sprays with their innovative film technology.

This approach maximizes the value they bring to patients, healthcare providers, and investors. Among their pipeline of products is a Sumatriptan Alginatfilm for the treatment of migraines, as well as an Epinephrine/Adrenaline Aliginatfilm to replace the outdated and bulky EpiPen technology, offering a more convenient, cost-effective, and superior alternative. They also have a Sirolimus film to address the variability in treatment efficacy and safety for organ transplant recipients.

Klaria has also ventured into the cannabis market with their subsidiary, Cannabis Delivery Sciences, aiming to create a new patented category of cannabis products formulated with their Alginatfilm. This new category combines the best of edible and smokable cannabis products without their respective drawbacks. With a commitment to innovation and patient-centered solutions, Klaria is revolutionizing drug delivery